Study confirms benefits of MiStent for CAD-Micell Technologies

Results of a comprehensive analysis of optical coherence tomography following implantation with MiStent SES, from Micell Technologies, in patients with Coronary Artery Disease demonstrated excellent vessel healing with a low rate of neoatherosclerosis. Data were additional findings from Micell's DESSOLVE I trial of MiStent SES, in which 30 patients with coronary artery disease were enrolled. Results showed lower rates of neoatherosclerosis following MiStent SES implantation as compared to previously reported results with other drug-eluting stents. It also demonstrated high rates of stent coverage in early follow-up, with further improvement at 18 months' follow-up.

The analysis showed stent strut malapposition that was low at all time points, and an established trend toward additional reduction at 18 months, and NIH thickness, area and volume remained static from eight to 18 months without evidence of late restenosis. The study was published in The American Journal of Cardiology. See: "Serial Assessment of Early and Late Vascular Responses After Implantation of an Absorbable-Coating Sirolimus-Eluting Stent: An Optical Coherence Tomography Sub-Study From The First-in-Human DESSOLVE I Trial." Guilherme Attizzani et al. The American Journal of Cardiology, November 15, 2013